These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 30463611

  • 1. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM, Others investigators (SERC trial group).
    BMC Cancer; 2018 Nov 21; 18(1):1153. PubMed ID: 30463611
    [Abstract] [Full Text] [Related]

  • 2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.
    Eur J Surg Oncol; 2017 Apr 21; 43(4):672-679. PubMed ID: 28139362
    [Abstract] [Full Text] [Related]

  • 3. Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial.
    Houvenaeghel G, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Gabelle P, Pernaut J, Del Piano F, D'Halluin G, Lantheaume S, Darai E, Beedassy B, Dhainaut-Speyer C, Martin X, Girard S, Villet R, Monrigal E, Hoyek T, Le Brun JF, Colombo PE, Tallet A, Boher JM, SERC trial group.
    NPJ Breast Cancer; 2021 Oct 08; 7(1):133. PubMed ID: 34625562
    [Abstract] [Full Text] [Related]

  • 4. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M.
    JAMA; 2017 Sep 12; 318(10):918-926. PubMed ID: 28898379
    [Abstract] [Full Text] [Related]

  • 5. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J.
    Breast Cancer Res Treat; 2019 Jan 12; 173(2):429-438. PubMed ID: 30315437
    [Abstract] [Full Text] [Related]

  • 6. [Sentinel node invasion: is it necessary to perform axillary lymph node dissection? Randomized trial SERC].
    Houvenaeghel G, Resbeut M, Boher JM.
    Bull Cancer; 2014 Apr 12; 101(4):358-63. PubMed ID: 24793627
    [Abstract] [Full Text] [Related]

  • 7. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
    Sávolt A, Polgár C, Musonda P, Mátrai Z, Rényi-Vámos F, Tóth L, Kásler M, Péley G.
    Clin Breast Cancer; 2013 Oct 12; 13(5):364-70. PubMed ID: 23773380
    [Abstract] [Full Text] [Related]

  • 8. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
    Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM.
    Cancer Med; 2023 Feb 12; 12(4):4023-4032. PubMed ID: 36127853
    [Abstract] [Full Text] [Related]

  • 9. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Riedel F, Heil J, Feißt M, Rezai M, Moderow M, Sohn C, Schütz F, Golatta M, Hennigs A.
    Breast Cancer Res Treat; 2019 Sep 12; 177(2):457-467. PubMed ID: 31236814
    [Abstract] [Full Text] [Related]

  • 10. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF.
    Dan Med J; 2012 Jul 12; 59(7):B4475. PubMed ID: 22759850
    [Abstract] [Full Text] [Related]

  • 11. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Malter W, Hellmich M, Badian M, Kirn V, Mallmann P, Krämer S.
    Anticancer Res; 2018 Jun 12; 38(6):3657-3662. PubMed ID: 29848724
    [Abstract] [Full Text] [Related]

  • 12. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
    Majid S, Rydén L, Manjer J.
    BMC Cancer; 2019 Jun 25; 19(1):626. PubMed ID: 31238899
    [Abstract] [Full Text] [Related]

  • 13. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM, Spronk PER, Vugts G, van Dalen T, Peeters MTFDV, Rots ML, Kuijer A, Nieuwenhuijzen GAP, Schipper RJ.
    Ann Surg; 2018 Dec 25; 268(6):1084-1090. PubMed ID: 28742702
    [Abstract] [Full Text] [Related]

  • 14. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC, Voogd AC, Tjan-Heijnen VC, Roumen RM.
    Eur J Surg Oncol; 2016 Aug 25; 42(8):1162-8. PubMed ID: 27265036
    [Abstract] [Full Text] [Related]

  • 15. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A, Riedel F, Feißt M, Köpke M, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Heil J.
    Ann Surg Oncol; 2019 Aug 25; 26(8):2435-2443. PubMed ID: 31049766
    [Abstract] [Full Text] [Related]

  • 16. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T, SENOMAC Trialists’ Group.
    Lancet Oncol; 2024 Sep 25; 25(9):1222-1230. PubMed ID: 39121881
    [Abstract] [Full Text] [Related]

  • 17. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G, Knauer M, Ribi K, Hayoz S, Gérard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, Mátrai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP.
    Trials; 2018 Dec 04; 19(1):667. PubMed ID: 30514362
    [Abstract] [Full Text] [Related]

  • 18. The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study.
    Poodt IGM, Rots ML, Vugts G, van Dalen T, Kuijer A, Vriens BEPJ, Nieuwenhuijzen GAP, Schipper RJ.
    Eur J Surg Oncol; 2018 Aug 04; 44(8):1151-1156. PubMed ID: 29580733
    [Abstract] [Full Text] [Related]

  • 19. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
    Houvenaeghel G, Boher JM, Reyal F, Cohen M, Garbay JR, Classe JM, Rouzier R, Giard S, Faure C, Charitansky H, Tunon de Lara C, Daraï E, Hudry D, Azuar P, Gimbergues P, Villet R, Sfumato P, Lambaudie E.
    Eur J Cancer; 2016 Nov 04; 67():106-118. PubMed ID: 27640137
    [Abstract] [Full Text] [Related]

  • 20. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F, Heil J, Feisst M, Moderow M, von Au A, Domschke C, Michel L, Schaefgen B, Golatta M, Hennigs A.
    Breast Cancer Res Treat; 2020 Nov 04; 184(2):627-636. PubMed ID: 32816190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.